Polatuzumab vedotin and CD79B: A study of efficacy in R-CHOP-resistant diffuse large B-cell lymphoma

Br J Haematol. 2025 Dec;207(6):2550-2552. doi: 10.1111/bjh.70185. Epub 2025 Oct 7.

Nicolas Munz¹, Alberto J Arribas^{1

2}, Roberta Bordone Pittau³, Federico Simonetta^{4

5}, Georg Stussi^{3

6}, Francesco Bertoni^{1

3}

¹ Faculty of Biomedical Sciences, Institute of Oncology Research, USI, Bellinzona, Switzerland.
² SIB Swiss Institute of Bioinformatics, Lausanne, Switzerland.
³ Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale (EOC), Bellinzona, Switzerland.
⁴ Division of Hematology, Department of Oncology, Geneva University Hospitals, University of Geneva, Geneva, Switzerland.
⁵ Faculty of Medicine, Translational Research Centre in Onco-Haematology, University of Geneva, Geneva, Switzerland.
⁶ Faculty of Biomedical Sciences, USI, Lugano, Switzerland.

No abstract available

Keywords: CD79B; DLBCL; R‐CHOP; antibody–drug conjugate; disulfiram; loncastuximab tesirine; lymphoma; polatuzumab vedotin.

Grants and funding